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Recently, genome wide association studies showed that there is a strong association between abacavir-induced serious, idio-
syncratic, adverse drug reactions (ADRs) and human leukocyte antigen-B*5701 (HLA-B*5701). Studies also found that ab-
acavir-induced ADRs were seldom observed in patients carrying the HLA-B*5801 subtype. HLA-B*5801 of the same sero-
type (B17) as B*5701 differs by only 4 amino acids from B*5701. It is believed that because of these sequence differences, 
HLA-B*5801 cannot bind the specific peptides which are required for HLA-B*5701 to stimulate the T cell immune response. 
Thus, the difference in peptide binding profiles between HLA-B*5701 and B*5801 is an important clue for exploring the 
mechanisms of abacavir-induced ADRs. VHSE (principal component score vector of hydrophobic, steric, and electronic prop-
erties), a set of amino acid structural descriptors, was employed to establish QSAR models of peptide-binding affinities of 
HLA-B*5701 and B*5801. Optimal linear SVM (support vector machine) models with high predictive capabilities were ob-
tained for both B*5701 and B*5801. The R2 (coefficient of determination), Q2 (cross-validated R2), and RPRE
2 (R2 of test set) of 
two optimal models were 0.7530, 0.7037, 0.6153 (B*5701) and 0.6074, 0.5966, 0.5762 (B*5801), respectively. For B*5701 
and B*5801, the mutations in positions 45 (MET-THR) and 46 (ALA-GLU) have little influence on the selection specificity of 
the P2 position of the bound peptide. However, the mutation in position 97 (VAL-ARG) greatly influences the selection speci-
ficity of the P7 position. HLA-B*5701 prefers the bulky and positively charged amino acids at the P7 position. In contrast, 
HLA-B*5801 prefers the non-polar hydrophobic amino acids at the P7 position while positively charged amino acids are un-
favored. 
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The rapid development of high-throughput and high-preci-    
sion whole-genome sequencing technologies has led to the 
frequent use of genome-wide association studies (GWAS) 
to detect connections between serious, idiosyncratic, ad-
verse drug reactions (ADRs) and human leucocytes antigens 
(HLAs) [1,2]. The association between abacavir hypersensi-
tivity and HLA-B*5701 has been studied intensively. The 
clinical symptoms of abacavir hypersensitivity are fever, 
rash, nausea, vomiting, gastrointestinal symptoms, and leth-
argy or malaise, and can be life-threatening [3]. In 2002, 
Hetherington, Mallal et al. [4,5] proposed that abacavir hy-
persensitivity was strongly associated with HLA-B*5701, 
particularly among Caucasians [6]. Moreover, Chessman [7] 
observed that abacavir could activate abacavir-specific 
CD8+ T cells to produce IFNγ and TNFα and induce 
HLA-B*5701-restricted hypersensitivity. Thus abacavir 
hypersensitivity reactions may depend on the conventional 
MHC-І antigen presentation pathway. 
In order to explain idiosyncratic adverse drug reactions, 
in 2006, Gerber [8,9] explored the P-I concept, or more 
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generally, the pharmacologic interaction of drugs with im-
mune receptors. The idea is that drugs can bind directly to 
the immune receptor molecules, namely the T cell receptor 
(TCR) and pHLA complex, by non-covalent interaction to 
elicit T-cell immune responses. The “P-I” concept was then 
proved by a series of experiments [10–13]. 
According to the “P-I concept”, non-covalent interactions 
among a drug, TCR, and pHLA, which alter the interface 
properties between pHLA and TCR are a key step to elicit 
ADRs. HLA-B*5701 and B*5801 of the same HLA-B17 
serotype have very similar peptide repertoires and differ in 
their amino acid sequences at only 4 positions [14]. How-
ever, research indicated that abacavir-specific CD8+ T cells 
were only stimulated in the presence of HLA-B*5701. It is 
generally accepted that specific peptides involved in ab-
acavir-induced ADRs cannot be selected by HLA-B*5801 
for T cell recognition [11]. In 2010, Bharadwaj [15] suc-
cessfully eluted an antigenic ligand from HLA-B*5701-       
positive patients treated with abacavir. This ligand was then 
proven to selectively stimulate abacavir specific T cells. 
Thus, the difference in peptide binding profiles between 
HLA-B*5701 and B*5801 is very important for exploring 
the mechanisms of abacavir-induced ADRs. 
Herein, we describe the use of a support vector machine 
(SVM) and multiple step-wise regression (MSR) [16] to 
establish quantitative structural-activity relationship (QSAR) 
models for predicting the binding affinities of peptides 
bound to HLA-B*5701 and B*5801. The QSAR models can 
provide quantitative characterizations of the differences in 
peptide-binding profiles of HLA-B*5701 and B*5801. 
These results should prove important for exploring the 
mechanisms of HLA-B*5701-restricted ADRs as well as for 
designing epitope-based vaccines. 
1  Principles and methods 
1.1  Data processing 
In October 2011, 1895 9-mer peptide ligands of HLA-    
B*5701 and 3069 9-mer peptide ligands of HLA-B*5801 
were extracted from the Immune Epitope Database (IEDB) 
[17,18]. After removing duplicate samples and samples with 
missing values, 1155 and 1867 ligands were finally ob-
tained for HLA-B*5701 and HLA-B*5801, respectively. 
The ligands with EC50>20000 were considered to be 
non-binders. In order to decrease the modeling error 
brought about by non-binders, the number of binders and 
non-binders were kept the same in both training and test sets. 
A total of 99 binders and 99 non-binders of HLA-B*5701 
were randomly selected from 198 binders and 957 
non-binders to construct a training set. The remaining 99 
binders together with 99 non-binders randomly selected 
were used to construct a test set. A total of 224 binders and 
224 non-binders of HLA-B*5801 were randomly selected 
from 448 binders and 1419 non-binders to build a training 
set. The remaining 224 binders and 224 non-binders ran-
domly selected were used to build a test set. The binding 
affinity of peptide ligand was defined as the negative loga-
rithm of 50% effective concentration (lgEC50). 
1.2  Structural description of peptide ligand 
VHSE, a set of amino acid descriptors, was derived from 
the research of Mei et al. [19]. Fifty physico-chemical 
properties of 20 coded amino acids, consisting of 18 hy-
drophobic properties, 17 steric properties, and 15 electronic 
properties, were used for principal component analysis 
(PCA). For the matrices of hydrophobic, steric, and elec-
tronic properties, the first 2, 2, and 4 principal components 
accounted for 74.33%, 78.68%, and 77.97% variance of the 
original data matrices, respectively. That is to say, the hy-
drophobic, steric, and electronic properties of 20 coded 
amino acids can be characterized by 8 principal component 
scores with minimal loss of information. These 8 score 
vectors are called the VHSE (principal components score 
vectors of hydrophobic, steric, and electronic properties) 
descriptors [19]. For the 20 amino acids, VHSE1 and 
VHSE2 are related to hydrophobic properties, VHSE3 and 
VHSE4 to steric properties, and VHSE5 to VHSE8 to elec-
tronic properties (Table 1).  
For the 9-mer peptide ligand described in this paper, each 
sample can be characterized by 72 (9×8) VHSE descriptors 
denoted by Vij, in which i indicates the position of the amino 
acid and j is the index of the VHSE descriptor. For example, 
V13 represents the VHSE3 descriptor of position 1. 
1.3  MSR-SVM modeling 
MSR combined by SVM was used to screen variables and 
construct QSAR models. MSR is an effective method to 
find an optimal subset in the original variable space, espe-
cially when the number of variables is not too large. SVM 
can avoid an over-fitting problem which often occurs in 
MSR modeling. Thus, MSR-SVM is a good choice for use 
in QSAR modeling for small datasets. 
The basic principle of SVM [16,20,21] is to find an op-
timal hyperplane to separate two classes of data with a large 
margin between them. In a nonlinear case, the data are 
mapped into a high-dimensional feature space where a line-
ar decision boundary is computed. SVM can be applied not 
only to classification problems but also to regression. SVM 
can fit a target function with a given accuracy  (  0), 
when the distances between data points and the optimal 
hyperplane are less than . The kernel function, i.e., K(x, 
xi)=(x)·(xi), is the core technology of SVM, and its use 
helps to avoid the problems of dimension disaster and de-
crease computational complexity. 
Based on experience in predicting peptide binding affini- 
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ties [22–24], the radial basis function (RBF) and linear ker-
nel function were used for SVM modeling. R2 (coefficient 
of determination), Q2 (10-fold cross-validated R2), RMS 
(root of mean squared error), and RPRE
2 (R2 of a test set) 
were used to evaluate the resulting QSAR models. Herein, 
RPRE
2 was defined as the R2 of a regression line through the 
origin for the test set. 
2  Results  
2.1  MSR-SVM modeling 
After screening by MSR, 4 and 5 optimal variable subsets 
were obtained for HLA-B*5701 and HLA-B*5801, respec-
tively. SVM models established by using each variable 
subset are shown in Table 2 and Table 3. The modeling 
performances of the RBF kernel were better than that of the 
linear kernel, but there were no significant differences be-
tween them.  
After considering the robustness, predictive powers, 
complexities and interpretabilities of the SVM models, 
model 5 with 14 VHSE variables (Table 2) and model 4 
with 15 VHSE variables (Table 3) were selected as the op-
timal linear models of HLA-B*5701 and HLA-B*5801, 
respectively. 
For HLA-B*5701 and HLA-B*5801, the binding affini-
ties of the test sets were predicted by model 5 and model 4, 
respectively. From Figures 1 and 2, it can be seen that mod-
el 5 and model 4 are predictive for the external datasets. The 
RPRE
2 and slopes of the two regression lines were 0.6153, 
0.9818 (B*5701) and 0.5762, 0.9759 (B*5801), respectively. 
Table 1  VHSE scales for 20 coded amino acids 
AA VHSE1 VHSE2 VHSE3 VHSE4 VHSE5 VHSE6 VHSE7 VHSE8 
Ala  A        
Arg  R        
Asn  N        
Asp  D        
Cys  C        
Gln  Q        
Glu  E        
Gly  G        
His  H        
Ile   I        
Leu  L        
Lys  K        
Met  M        
Phe  F        
Pro  P        
Ser  S        
Thr  T        
Trp  W        
Tyr  Y        
Val  V        
Table 2  The performance of the SVM models on the peptide binding affinities of HLA-B*5701 
ID No. of variables Kernal C   R2 RMS Q2(10-fold) RPRE2 
1 72 
Linear 1.9691 0.0317  0.7083 0.7013 0.6055 0.5386 
RBF 16.4872 0.0811  0.9957 0.6542 0.6544 0.6031 
2 32 
Linear 42.1016 0.3012  0.7882 0.5918 0.7273 0.6149 
RBF 12.0623 0.1716  0.9316 0.5730 0.7449 0.6244 
3 25 
Linear 10.6449 0.0672  0.7450 0.6042 0.7121 0.5746 
RBF 39.5508 0.0026  0.8320 0.5845 0.7282 0.5765 
4 18 
Linear 10.000 0.3679  0.7712 0.6078 0.7068 0.6130 
RBF 5.3526 0.3012  0.8140 0.5840 0.7270 0.6465 
5 14 
Linear 27.1828 0.3679  0.7530 0.6037 0.7037 0.6153 
RBF 10.0000 0.3679 1.3591 0.7964 0.6009 0.7061 0.6761 
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Table 3  The performance of the SVM models on the peptide binding affinities of HLA-B*5801 
ID No. of variables Kernal C   R2 RMS Q2(10-fold) RPRE2 
1 72 
Linear 10.0000 0.3679  0.6213 0.8510 0.5674 0.5709 
RBF 4.7237 0.1180  0.7759 0.8197 0.5977 0.5929 
2 35 
Linear 25.5359 0.2497  0.6420 0.8076 0.6090 0.5088 
RBF 23.9888 0.1716  0.7917 0.7733 0.6404 0.5453 
3 28 
Linear 65.2082 0.2346  0.6167 0.8019 0.6164 0.4968 
RBF 21.1700 0.3012  0.7293 0.7789 0.6362 0.5537 
4 15 
Linear 27.1828 0.3679  0.6074 0.8220 0.5966 0.5762 




Figure 1  Observed vs. predicted peptide binding affinities of 
HLA-B*5701. 
 
Figure 2  Observed vs. predicted peptide binding affinities of 
HLA-B*5801. 
The optimized model 5 and model 4 were further vali-
dated by 10 repeated random samplings. By using the same 
variable subsets and parameters, 10 linear SVM models 
were obtained for each model. For HLA-B*5701 and 
HLA-B*5801, the average R2, Q2, RPRE
2 of the 10 models 
were 0.6958, 0.6661, 0.6557 (B*5701) and 0.6027, 0.5926, 
0.5796 (B*5801), respectively. 
2.2  Peptide binding specificities of HLA-B*5701 and 
HLA-B*5801 
HLA-B*5701 and B*5801 belong to the HLA-B17 serotype, 
and differ at 4 amino acid positions in the peptide-binding 
groove composed by the 1 and 2 domains (Figure 3). 
Residues 45 and 46 are located in the B pocket of the pep-
tide-binding groove and can interact with the dominant an-
chor residue in position 2 (P2) of the 9-mer peptide. Resi-
due 97 located between pocket C and E can interact with the 
secondary anchor residue in position 7 (P7) [25]. Therefore, 
mutations at these 3 positions play important roles in the 
binding specificities of the P2 and P7 positions. Residue 
103 is not in the peptide binding groove, so it has no signif-
icant effect on peptide binding specificities. 
The entrance of the B pocket of B*5701 is mainly com-
posed of the bulky residues TYR7, ASN66 and GLU63, and 
the bottom primarily consists of the hydrophobic residues 
VAL24, GLY26, MET45 and ALA46 (Figure 4A). Com-
pared to B*5701, position 45 of B*5801 is substituted by a 
hydrophilic THR and position 46 by a negatively charged 
GLU (Figure 4B). Thus, pocket B of B*5801 is more hy-
drophilic than that of B*5701. However, the negatively 
charged GLU46 located in the far end of the bottom pocket 
has little influence on the selection specificity of P2 of a 
bound peptide.  
Residue 97 is located between the E and C pockets of the 
binding groove. For both B*5701 and B*5801, pocket E is 
mainly composed of VAL152, TRP147, LEU156, TRP133, 
ASP114 and SER116 (Figure 4C). It is important to note 
that the negatively charged ASP114 and SER116 located in 
the bottom of the E pocket have proved to be closely related 
to the abacavir-induced ADRs. Position 97 of B*5701 is 
occupied by a small hydrophobic VAL, whereas position 97 
of B*5801 is occupied by a bulky and positively charged 
ARG. Thus, the E pocket of B*5701 is more negatively 
charged and is less sterically hindered than that of B*5801.  
2.2.1  Peptide binding specificity of HLA-B*5701 
The weight coefficients of the 14 VHSE variables included 
in model 5 are shown in Figure 5. These 14 VHSE variables  
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Figure 3  Models of HLA-B*5701 and B*5801. 
 
Figure 4  The B and E pockets of HLA-B*5701 and B*5801. A, Lipophilic potential properties of the B pocket of B*5701. B, Lipophilic potential proper-
ties of the B pocket of B*5801. C, Electrostatic potential properties of the E pocket of B*5701. D, Electrostatic potential properties of the E pocket of  
B*5801. 
characterize the hydrophobic, steric, and electronic proper-
ties of P1, P2, P3, P4, P5, P7 and P9 positions. From the 
absolute values of the weight coefficients, it can be seen 
that P2 and P9 significantly contribute to the binding affini-
ties of the bound peptides, followed by P1, P3 and P7, then 
P4 and P5. P6 and P8 do not contribute to the binding affin-
ities. 
Templated by an “AAAAAAAAA” sequence, a virtual 
9-mer peptide library was constructed by a single point mu-
tation at each position using each of the other 19 amino ac-
ids. For each position, a total of 19 mutated peptides to-
gether with the template were predicted by model 5. Then, 
the predicted binding affinities of the 20 peptides were sub-
jected to auto-scaled treatment. Thus, the scales at 9 amino 
acid positions (Table 4) can characterize the binding profile 
of B*5701.  
In model 5, 4 VHSE variables of the P2 position repre-
sent steric (V23, V24) and electronic properties (V25, V26). 
According to the peptide binding profile shown in Table 4, 
small or polar amino acids like ALA, GLY, SER, THR and 
CYS are favored at this position, whereas TRP, TYR, GLU 
and ARG are disfavored.  
Three VHSE variables of the P9 position characterize 
hydrophobic (V91), steric (V93) and electronic (V98) proper- 
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Figure 5  The weight coefficients of the VHSE variables of the 
HLA-B*5701 model. 
ties. Table 4 indicates that bulky or hydrophobic amino ac-
ids like TRP, PHE, TYR, LEU and MET are favored at this 
position, while PRO and ASP are disfavored. 
The profile of P7 is characterized by 2 VHSE variables 
representing steric (V71) and electronic (V76) properties re-
spectively. According to Table 4, the bulky and positively 
charged ARG, HIS and LYS are desirable at P7, whereas 
small and hydrophobic GLY, ALA and PRO are undesira-
ble. 
Two VHSE variables of the P3 position represent elec-
tronic properties (V35, V37). The hydrophobic or bulky CYC, 
PHE, TRP and TYR are favored at this position, whereas 
GLY, GLU and ASP are disfavored. For positions P1 (V15), 
P4 (V48) and P5 (V54), each has only 1 VHSE variable. 
Therefore, these positions have less influence on peptide 
binding.  
2.2.2  Peptide binding specificity of HLA-B*5801 
For HLA-B*5801, 15 VHSE variables included in model 4 
are related to P1, P2, P3, P4, P5, P7 and P9 positions. From 
the weight coefficients of the VHSE variables (Figure 6), it 
can be concluded that P2 and P9 have the most influence on 
the binding affinity, followed by P7, P3, P1 and P4, then P5. 
P6 and P8 have no contributions to the binding affinity ac-
cording to model 4. 
Based on the standardized predicted values of the mutat-
ed peptides, the peptide binding profiles of B*5801 are 
shown in Table 5, and were used for the following analysis. 
The 4 VHSE variables of the P2 position represent steric 
(V23, V25) and electronic properties (V27, V28) respectively. 
From Table 5, it can be deduced that the small or neutral 
amino acids GLY, ALA, SER, CYS and THR are preferred, 
while the charged or bulky ARG and TRP are not preferred 
at this position. This profile is similar to that of B*5701, 
which only differs in the order of preference.  
Two VHSE variables of P9 describe the hydrophobic 
(V91) and steric (V93) properties. According to the weight 
coefficients, the contributions of these 2 variables are larger  
 
Figure 6  The weight coefficients of the VHSE variables of the 
HLA-B*5801 model. 
than that of B*5701. However, compared with B*5701, the 
electronic property (V98) has no contribution to the peptide 
binding affinity. According to Table 5, the bulky or hydro-
phobic TRP, PHE and TYR are favored at P9, whereas 
GLY, SER and ALA are disfavored. 
Three VHSE variables of P7 characterize the hydropho-
bic (V71) and electronic (V75, V76) properties. As indicated in 
Table 5, the hydrophobic PHE, TRP and MET are preferred 
at this position. However, the electronic properties (V75, V76) 
of P7 should also be considered. For instance, a negatively 
charged ASP is favored at this position, while the positively 
charged ARG and LYS are disfavored. For B*5801, muta-
tion at position 97 (VAL-ARG) alters the physio-chemical 
properties of the surface of pocket E, and thus changes the 
selection specificity at the P7 position. That is, bulky and 
positively charged residues at P7 are preferred for B*5701, 
while hydrophobic residues are preferred for B*5801.  
P3 (V37, V38) and P4 (V46, V48) both involve 2 VHSE var-
iables for characterization of their electronic properties. 
From Table 5, it can be deduced that TRP, CYC, MET and 
PHE are favored at P3, while PRO, ARG and LYS are dis-
favored. Also, PRO is preferred at P4 position, but ASN 
should be avoided. 
P1 (V15) and P5 (V52) each involve one VHSE variable, 
representing the electronic and hydrophobic properties, re-
spectively. It can be seen that LYS and ARG are favored at 
P1, while CYC and GLY are favored at P5 (Table 5). 
Overall, there is a notable difference in the binding spec-
ificity of P7 between HLA-B*5701 and B*5801, and little 
differences in P1, P2, P3, P4, P5 and P9. Thus, it can be 
inferred that the amino acid preference at the P7 position of 
HLA-B*5701 is closely related to abacavir-induced ADRs. 
3  Discussion 
Genome-wide association studies indicate that there is a 
strong association between abacavir-induced ADRs and  
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Table 4  Peptide binding profile of HLA-B*5701 
 P1 P2 P3 P4 P5 P7 P9 
Ala  A       
Arg  R       
Asn  N       
Asp  D       
Cys  C       
Gln  Q       
Glu  E       
Gly  G       
His  H       
Ile   I       
Leu  L       
Lys  K       
Met  M       
Phe  F       
Pro  P       
Ser  S       
Thr  T       
Trp  W       
Tyr  Y       
Val  V       
Table 5  Peptide binding profile of HLA-B*5801 
 P1 P2 P3 P4 P5 P7 P9 
Ala  A       
Arg  R       
Asn  N       
Asp  D       
Cys  C       
Gln  Q       
Glu  E       
Gly  G       
His  H       
Ile   I       
Leu  L       
Lys  K       
Met  M       
Phe  F       
Pro  P       
Ser  S       
Thr  T       
Trp  W       
Tyr  Y       
Val  V       
 
HLA-B*5701. According to the P-I concept, non-covalent 
binding between abacavir and immune receptors is a key 
step to elicit ADRs. It is commonly speculated that specific 
peptides exclusively presented by HLA-B*5701 are in-
volved in abacavir-induced ADRs. Therefore, comparison 
of peptide binding specificity between HLA-B*5701 and 
B*5801 is very important for exploring the mechanisms of 
abacavir-induced ADRs. 
Based on a VHSE structural description method, QSAR 
models of peptide-binding affinities for HLA-B*5701 and 
B*5801 were established by the MSR-SVM method. Two 
optimal SVM models with strong predictive power were 
obtained. The results show that P2, P9, P1, P3 and P7 have 
significant influence on the binding affinities of both 
B*5701 and B*5801, followed by P4 and P5. A comparison 
of the peptide binding profiles of B*5701 and B*5801 indi-
cated that mutations at positions 45 (MET-THR) and 46 
(ALA-GLU) have little influence on the selection specifici-
ty of the P2 position. However, the mutation at position 97 
(VAL-ARG) has significant influence on the selection spec-
 Zhang Y L, et al.   Sci China Life Sci   September (2012) Vol.55 No.9 825 
ificity of P7. Also, for B*5701, bulky and positively 
charged residues are preferred at P7, while for B*5801 hy-
drophobic residues are preferred at this position. Thus, the 
amino acid preference at P7 of the bound peptides of 
HLA-B*5701 is inferred to be closely related to abacavir-        
induced ADRs. In conclusion, these results should prove to 
be a valuable reference for exploring the mechanisms of 
abacavir-induced ADRs. 
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